PD-1/PD-L1 in disease

Nyanbol Kuol, Lily Stojanovska, Kulmira Nurgali, Vasso Apostolopoulos

Research output: Contribution to journalReview articlepeer-review

53 Citations (Scopus)

Abstract

Aim: Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor signal transduction. PD-L1 and PD-1 blockade using antibodies are in human clinical trials as an alternative cancer treatment modality. Areas covered: We describe the role of PD-1/PD-L1 in disease in the context of autoimmunity, neurological disorders, stroke and cancer. Conclusion: For immunotherapy/vaccines to be successful, the expression of PD-L1/PD-1 on immune cells should be considered, and the combination of checkpoint inhibitors and vaccines may pave the way for successful outcomes to disease.

Original languageEnglish
Pages (from-to)149-161
Number of pages13
JournalImmunotherapy
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2018
Externally publishedYes

Keywords

  • PD-1
  • PD-L1
  • autoimmune disease
  • cancer
  • neurological disease
  • vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'PD-1/PD-L1 in disease'. Together they form a unique fingerprint.

Cite this